Steris (NYSE:STE) 주식

Steris

Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Additionally, Steris sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 19% from Applied Sterilization Technologies, or AST, and 11% from life sciences services after the divestment of its dental products business.

What Happened

Upgrades

Markets

Analyst Ratings

Trading Ideas

TSLA

월스트리트의 주요 애널리스트들이 이들 주요 기업들에 대한 전망을 변경했다. 애널리스트의 모든 등급 변경 사항을 완전하게 보려면, 애널리스트 등급 페이지를 참조하세요.

테슬라 분석가가 긍정적으로 전환; 목요일 업그레이드 상위 5종목

Top Performer

News

Movers

EQIX

TEVA

TOST

이들 대형주들은 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?테바 파마슈티컬 인더스트리즈(NYSE:TEVA)의 주가는 회사가 엇갈린 1분기 재무 결과를 발표하고 위약과 비교하여 정신분열증이 있는 성인 환자를 대상으로 한 TEV-&#39;749의 3상 솔라리스(SOLARIS) 시험의 효능 부분 결과를 발표했한 후 16.24% 급등했다. 

지난주(5월 5일~5월 11일) 최고의 성과를 낸 10개의 대형주

Steris PLC

SM ENTMT JAPAN CO LTD by SM ENTMT JAPAN CO LTD

Sm Entertainment Japan Co Ltd

Santech Holdings Limited - American Depositary Shares

Santech Holdings Ltd

Scatec ASA

STEER Technologies Inc Ordinary Shares

Steem

STATE ENERGY GRP by STATE ENERGY GROUP INTL ASSETS HLDGS LTD.

Majestic Dragon AeroTech Holdings Ltd

Sintana Energy Inc Warrants (08/03/2024)

Stemtech Corp

Stellar Bancorp Inc

Stem Inc

StepStone Group Inc. - Class A Common Stock

StepStone Group Inc

Step Finance - United States Dollar

STERLING CHECK CORP COM

Lido stETH

Stevia Corp

SRH Total Return Fund, Inc.

A large exercise of company stock options by Kenneth Kohler, SVP &amp; GM at Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) was disclosed in a new SEC filing on June 5, as part of an insider exercise.
What Happened: Kohler, SVP &amp; GM at Steris, made a strategic move by exercising stock options for 0 shares of STE as detailed in a Form 4 filing on Thursday with the <a href="https://www.sec.gov/Archives/edgar/data/0001757898/000162828025029701//Archives/edgar/data/1757898/000162828025029701/0001628280-25-029701-index.htm">U.S. Securities and Exchange Commission</a>. The transaction value amounted to $0.
During Friday's morning session, Steris shares down by 0.0%, currently priced at $243.58. Considering the current price, Kohler's 0 shares have a total value of $0.
<h3>About Steris</h3>
Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Additionally, Steris sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 19% from Applied Sterilization Technologies, or AST, and 11% from life sciences services after the divestment of its dental products business.
<h3>Financial Insights: Steris</h3>
Revenue Growth: Over the 3 months period, Steris showcased positive performance, achieving a revenue growth rate of 4.31% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Evaluating Earnings Performance:
<ul>
<li>
Gross Margin: The company shows a low gross margin of 43.31%, indicating concerns regarding cost management and overall profitability relative to its industry counterparts.
</li>
<li>
Earnings per Share (EPS): Steris's EPS outshines the industry average, indicating a strong bottom-line trend with a current EPS of 1.48.
</li>
</ul>
Debt Management: Steris's debt-to-equity ratio is below the industry average at 0.33, reflecting a lower dependency on debt financing and a more conservative financial approach.
Evaluating Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: Steris's P/E ratio of 39.54 is below the industry average, suggesting the stock may be undervalued.
</li>
<li>
Price to Sales (P/S) Ratio: With a lower-than-average P/S ratio of 4.42, the stock presents an attractive valuation, potentially signaling a buying opportunity for investors interested in sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With an EV/EBITDA ratio lower than industry averages at 19.13, Steris could be considered undervalued.
</li>
</ul>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Activity Matters in Finance</h3>
Emphasizing the importance of a comprehensive approach, considering insider transactions is valuable, but it's crucial to evaluate them in conjunction with other investment factors.
From a legal standpoint, the term "insider" pertains to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as outlined in Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and significant hedge funds. These insiders are mandated to inform the public of their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
A company insider's new purchase is a indicator of their positive anticipation for a rise in the stock.
While insider sells may not necessarily reflect a bearish view and can be motivated by various factors.
<h3>Transaction Codes Worth Your Attention</h3>
Examining transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often concentrate on those unfolding in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001757898">Check Out The Full List Of Steris's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Options Exercise Activity Initiated By Kenneth Kohler At Steris Worth $0

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Jefferies analyst David Windley initiated coverage on STERIS plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) with a Hold rating and announced a price target of $263. Steris shares closed at $245.00 on Wednesday. <a href="https://www.benzinga.com/quote/ste/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Richard Hightower initiated coverage on Sun Communities, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUI#NYSE">SUI</a>) with an Overweight rating and announced a price target of $141. Sun Communities shares closed at $120.77 on Wednesday. <a href="https://www.benzinga.com/quote/sui/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying SUI stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="583" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29084555/image-387-1024x583.png" alt="" class="wp-image-931535" style="width:611px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29084555/image-387-1024x583.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29084555/image-387-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29084555/image-387-768x437.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29084555/image-387.png 1121w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/25/05/45641430/jim-cramer-says-this-quantum-computing-stock-is-so-high-and-too-speculative">Jim Cramer Says This Quantum Computing Stock Is &#8216;So High&#8217; And &#8216;Too Speculative&#8217;</a> </li>
</ul>
Photo via Shutterstock

Initiation

Pre-Market Outlook

This Sun Communities Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Thursday

Jefferies analyst David Windley initiates coverage on Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) with a Hold rating and announces Price Target of $263.

Price Target

Jefferies Initiates Coverage On Steris with Hold Rating, Announces Price Target of $263

In the last three months, 4 analysts have published ratings on Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>), offering a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Steris, presenting an average target of $263.75, a high estimate of $280.00, and a low estimate of $250.00. Marking an increase of 3.43%, the current average surpasses the previous average price target of $255.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1747681251_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A comprehensive examination of how financial experts perceive Steris is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$260.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>David Turkaly</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$280.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Steven Etoch</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$250.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>David Turkaly</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$265.00</td>
<td>$265.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Steris. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Steris compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Steris's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Steris's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/STE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Steris analyst ratings.</a>
<h2>All You Need to Know About Steris</h2>
Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Additionally, Steris sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 19% from Applied Sterilization Technologies, or AST, and 11% from life sciences services after the divestment of its dental products business.
<h3>A Deep Dive into Steris's Financials</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Positive Revenue Trend: Examining Steris's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 8.02% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Steris's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 9.84%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Steris's ROE excels beyond industry benchmarks, reaching 2.24%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Steris's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.45%, the company showcases efficient use of assets and strong financial health.
Debt Management: Steris's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.31.
<h2>The Significance of Analyst Ratings Explained</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Steris Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

Morgan Stanley analyst Patrick Wood maintains Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) with a Equal-Weight and raises the price target from $240 to $260.

Morgan Stanley Maintains Equal-Weight on Steris, Raises Price Target to $260

JMP Securities analyst David Turkaly maintains Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) with a Market Outperform and raises the price target from $265 to $280.

JMP Securities Maintains Market Outperform on Steris, Raises Price Target to $280

WIIM

STERIS shares are trading higher after the company reported better-than-expected Q4 financial results and issued guidance above estimates.

U.S. stocks were lower, with the Nasdaq Composite falling around 100 points on Thursday.
Shares of Deere &amp; Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>) rose sharply during Wednesday's session following better-than-<a href="https://www.benzinga.com/quote/DE/earnings">expected quarterly results.</a>
Deere posted quarterly earnings of $6.64 per share, beating market estimates of $5.59 per share. The company's quarterly sales came in at $12.76 billion versus expectations of $10.79 billion.
Deere shares jumped 4.9% to $521.76 on Thursday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul class="wp-block-list">
<li>Foot Locker, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FL#NYSE">FL</a>) shares gained 82.7% to $23.51 after DICK&#8217;s Sporting Goods agreed to acquire the company. Also, the company issued preliminary Q1 non-GAAP EPS results.</li>
<li>Ibotta, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBTA#NYSE">IBTA</a>) jumped 20.8% to $60.57 after the company reported better-than-expected first-quarter financial results and Needham raised its price target on the stock from $60 to $70.</li>
<li>Boot Barn Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOOT#NYSE">BOOT</a>) gained 17% to $154.79 after the company issued first-quarter guidance with its midpoint above estimates and announced a $200 million share repurchase program.</li>
<li>DLocal Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLO#NASDAQ">DLO</a>) gained 15.7% to $11.79 after the company reported better-than-expected first-quarter EPS and sales.</li>
<li>NV5 Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVEE#NASDAQ">NVEE</a>) rose 15.4% to $21.76 after the company announced a merger agreement with Acuren.</li>
<li>Gaotu Techedu Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOTU#NYSE">GOTU</a>) gained 15.3% to $4.38 after the company reported a year-over-year increase in first-quarter sales results.</li>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) rose 13.7% to $390.00.</li>
<li>VEON Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEON#NASDAQ">VEON</a>) rose 13.3% to $55.46 after the company reported better-than-expected first-quarter EPS and sales.</li>
<li>NetEase, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTES#NASDAQ">NTES</a>) gained 13.1% to $121.13 after the company reported better-than-expected first-quarter earnings and sales.</li>
<li>Nextracker Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXT#NASDAQ">NXT</a>) rose 11.6% to $61.42 following upbeat quarterly results.</li>
<li>STERIS plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) gained 7.8% to $245.31 following strong quarterly earnings.</li>
<li>Cisco Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) jumped 5.7% to $64.81 after the company reported better-than-expected third-quarter financial results and raised its FY25 guidance.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45405004/jim-cramer-sofi-goes-to-new-highs-recommends-not-buying-this-health-care-stock">Jim Cramer: SoFi Goes To &#8216;New Highs,&#8217; Recommends Not Buying This Health Care Stock</a> </li>
</ul>
Photo via Shutterstock

Earnings

BOOT

CSCO

GSX Techedu Inc. American Depositary Shares

GOTU

IBTA

NTES

NVEE

VEON

Deere Posts Upbeat Earnings, Joins Foot Locker, Boot Barn, Cisco And Other Big Stocks Moving Higher On Thursday

Stephens &amp; Co. analyst Steven Etoch reiterates Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) with a Overweight and maintains $250 price target.

Reiteration

Stephens & Co. Reiterates Overweight on Steris, Maintains $250 Price Target

Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) is looking for FY2026 Adj EPS of $9.90-$10.15 vs $9.87 analyst estimate..

Guidance

Steris Sees FY2026 expects reported revenue from continuing operations to increase 6-7%.

Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) is looking for FY2026 GAAP EPS of $7.82-$8.07 vs $7.87 analyst estimate..

Steris Sees FY2026 GAAP EPS $7.82-$8.07 vs $7.87 Est

Steris Sees FY2026 Adj EPS $9.90-$10.15 vs $9.87 Est

Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) reported quarterly earnings of $2.74 per share which beat the analyst consensus estimate of $2.59 by 5.79 percent. This is a 13.69 percent increase over earnings of $2.41 per share from the same period last year. The company reported quarterly sales of $1.48 billion which beat the analyst consensus estimate of $1.47 billion by 0.81 percent. This is a 4.37 percent increase over sales of $1.42 billion the same period last year.

Earnings Beats

Steris Q4 Adj. EPS $2.74 Beats $2.59 Estimate, Sales $1.48B Beat $1.47B Estimate

U.S. tech stocks extended their weekly rally into Wednesday's session, lifted by renewed investor appetite for risk following a breakthrough in early-week U.S.-China trade negotiations. This reignited hopes for a more <a href="https://www.benzinga.com/topic/tariffs">stable global trade outlook. </a>
The Nasdaq 100 rose 0.5% by midday in New York, reaching levels last seen in late February. Heavyweight chipmakers led the rally, as Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) surged 4% and Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) jumped 5%.
Traders welcomed mounting expectations of large-scale investments from Gulf nations into U.S. tech and semiconductor sectors, as President Donald Trump secured new economic agreements with <a href="https://www.benzinga.com/25/05/45417156/nvidia-amd-stocks-climb-as-trump-plans-to-ease-ai-chip-export-rules">Middle Eastern countries</a>, including Saudi Arabia and Syria.
While the Nasdaq marched higher, the S&amp;P 500 stalled and both the Dow Jones Industrial Average and Russell 2000 slipped slightly, indicating a more selective rally focused on high-growth sectors.
Clean energy and solar stocks outperformed again, building on strong Tuesday gains. Investors cheered a less-severe-than-expected revision to clean energy tax credits in the latest Republican tax proposal.
The commodity space told a different story, with gold prices dropping nearly 2%, breaking below the $3,200 per ounce mark for the first time in over a month. 
The yellow metal is now tracking its worst weekly performance since November 2024, with two trading sessions still left this week.
Investors appear to be rotating out of safe-haven assets, as appetite for equities and riskier plays returns on global trade optimism. 
Rising Treasury yields also weighed on broader market sentiment. The yield on the 2-year Treasury note broke above 4%, hitting its highest level in more than two months. Meanwhile, the 30-year bond yield rose 5 basis points to 4.97%, drawing closer to the psychologically important 5% mark—a level often associated with tightening financial conditions and pressure on long-duration assets.
<h3 class="wp-block-heading">Wednesday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>21,273.30</td>
<td>0.4%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,891.20</td>
<td>0.1%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>42,075.32</td>
<td>-0.2%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,089.17</td>
<td>-0.6%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:15 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul class="wp-block-list">
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) flattened at $586.91.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) eased 0.3% to $420.45.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;rose 0.4% to $517.40.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) inched 0.6% lower to $207.35.</li>
<li>The&nbsp;Consumer Discretionary&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) outperformed, up 0.5%; the&nbsp;Health Care&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>) lagged, down 1.8%.</li>
</ul>
<h3 class="wp-block-heading">Wednesday&#8217;s Stock Movers</h3>
<ul class="wp-block-list">
<li>Israeli retail broker Etoro Group Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETOR#NASDAQ">ETOR</a>) made his debut on the Nasdaq 100 index. Shares were up 26%.</li>
<li>Super Micro Computer Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) rallied for a second straight session, jumping 18% to $45.99 on Monday after a 16% gain the previous day.</li>
<li>Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) advanced 1.9% after securing a major deal with Qatar Airways, which agreed to purchase up to 210 Boeing 787 Dreamliner and 777X aircraft in a transaction valued at $96 billion.</li>
<li>Exelixis Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) soared 20% after the biotech firm posted first-quarter earnings and revenue that topped Wall Street estimates.</li>
<li>Stocks slated to report earnings after the close include Cisco Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>), Copart Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRT#NASDAQ">CPRT</a>) and Steris plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>). </li>
</ul>
Now Read:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/government/regulations/25/05/45414023/magnificent-seven-add-36-trillion-since-april-lows-is-this-rally-just-beginning">Magnificent Seven Add $3.6 Trillion Since April Lows: Is This Rally Just Beginning?</a></li>
</ul>
Image: Shutterstock

Equities

Government

Large Cap

Regulations

Broad U.S. Equity ETFs

Econ #s

Tech

ETFs

CPRT

SPDR Dow Jones Industrial Average ETF Trust

ETOR

EXEL

NVDA

SMCI

Select Sector SPDR-Consumer Discretionary

Tech Stocks Edge Up, AMD Rallies 5%, 30-Year Yields Eye Danger Zone: What's Driving Markets Wednesday?

ADCT

AEVA

AFCG

ALUR

ARCO

ATER

AYTU

BCDA

BITF

BNGO

The Beachbody Company, Inc. Class A Common Stock

BODI

BRTX

BZAI

CAAS

CANG

CCAP

CDXS

CELC

CLBT

CLSD

CREX

CSPI

CSWC

CTSO

DAVA

DERM

DRIO

DYAI

EGAN

ELVA

EPSN

EWCZ

FIHL

FOSL

GCTS

GLBE

GROV

GWRS

HWKN

ICCC

INVZ

IREN

ISSC

ITRG

JACK

KARO

KITT

KMDA

KRNT

LAZR

LDTC

LIEN

LIQT

LOCL

LUCD

LUXE

LVLU

MDXH

MGRM

MMYT

NEXN

NSYS

NTWK

NVGS

NYXH

ONCY

PDSB

PYPD

RCAT

RDCM

REKR

RELI

RSKD

SBLK

SCPH

SDHC

SDOT

SDST

SGML

SHIM

Earnings Scheduled For May 14, 2025

Across the recent three months, 4 analysts have shared their insights on Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $258.75, a high estimate of $265.00, and a low estimate of $240.00. Marking an increase of 0.49%, the current average surpasses the previous average price target of $257.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1744322492_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The perception of Steris by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;-----------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;David Turkaly &#x7C;JMP Securities &#x7C;Maintains &#x7C;Market Outperform&#x7C; $265.00&#x7C;$265.00 &#x7C; 
&#x7C;Reni Benjamin &#x7C;JMP Securities &#x7C;Maintains &#x7C;Market Outperform&#x7C; $265.00&#x7C;$265.00 &#x7C; 
&#x7C;Jacob Johnson &#x7C;Stephens &amp; Co. &#x7C;Maintains &#x7C;Overweight &#x7C; $240.00&#x7C;$240.00 &#x7C; 
&#x7C;Jason Bednar &#x7C;Piper Sandler &#x7C;Raises &#x7C;Overweight &#x7C; $265.00&#x7C;$260.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Steris. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Steris compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Steris's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Steris's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/STE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Steris analyst ratings.</a>
<h2>About Steris</h2>
Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Additionally, Steris sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 19% from Applied Sterilization Technologies, or AST, and 11% from life sciences services after the divestment of its dental products business.
<h3>Steris's Economic Impact: An Analysis</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Over the 3M period, Steris showcased positive performance, achieving a revenue growth rate of 5.61% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Steris's net margin is impressive, surpassing industry averages. With a net margin of 12.66%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Steris's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.67% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Steris's ROA excels beyond industry benchmarks, reaching 1.71%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.36.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 4 Analysts Discuss Steris Stock

JMP Securities analyst David Turkaly reiterates Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) with a Market Outperform and maintains $265 price target.

JMP Securities Reiterates Market Outperform on Steris, Maintains $265 Price Target

Needham analyst Mike Matson reiterates Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) from Hold to Hold.

Needham Reiterates Hold on Steristo Hold

On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round,</a>&#8220; Jim Cramer recommended selling NANO Nuclear Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNE#NASDAQ">NNE</a>).
On March 7, NANO Nuclear Energy announced that Florent Heidet, Ph.D. has joined NANO Nuclear as its Chief Technology Officer and Head of <a href="https://www.benzinga.com/quote/NNE/news">Reactor Development</a>.
Cramer said Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) is a &#8220;challenged&#8221; company, and he doesn't really care for it.
RBC Capital analyst Conor McNamara, on March 12, maintained Illumina with an Outperform and lowered the price target from $247 to $128.
When asked about Archer Aviation Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>), he said, &#8220;Keep looking but do not press the button.&#8221;
As per the recent news, Archer Aviation and Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>), on March 13, collaborated to build the AI foundation for the future of advanced aviation technologies.
The Mad Money host said he has always liked STERIS plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) and recommended buying the stock. &#8220;I think it's just a strong company,&#8221; he added.
Supporting his view, Stephens &amp; Co. analyst Jacob Johnson, on Feb. 6, reiterated Steris with an Overweight rating and maintained a $240 price target.
Cramer said he doesn't know what Sixth Street Specialty Lending, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSLX#NYSE">TSLX</a>) really owns, so therefore he can't give his opinion on it.
RBC Capital analyst Kenneth Lee, on Feb. 26, maintained Sixth Street Specialty with an Outperform rating and raised the price target from $23 to $25.
Cramer said he likes Lam Research Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>) very much and recommended to own the stock.
Adding support to his choice, Susquehanna analyst Mehdi Hosseini, on Feb. 20, upgraded Lam Research from Neutral to Positive and raised the price target from $75 to $125.
Arista Networks Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>) has been an &#8220;amazing stock for many years,&#8221; Cramer said. He recommended buying the stock.
Supporting his view, UBS analyst David Vogt, on March 5, upgraded Arista Networks from Neutral to Buy and raised the price target from $112 to $115.
Price Action:
<ul>
<li>Illumina shares fell 0.2% to settle at $84.05 on Thursday.</li>
<li>Archer Aviation shares dipped 3.1% to close at $7.25 during the session.</li>
<li>NANO Nuclear Energy shares gained 1.9% to settle at $28.32.</li>
<li>Steris shares fell 0.9% to close at $222.45.</li>
<li>Sixth Street Specialty Lending shares fell 0.9% to close at $21.96 on Thursday.</li>
<li>Lam Research shares fell 1.7% to settle at $75.26.</li>
<li>Arista Networks shares fell 0.1% to close at $80.14 on Thursday.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44298504/top-3-health-care-stocks-youll-regret-missing-this-quarter">Top 3 Health Care Stocks You&#8217;ll Regret Missing This Quarter</a></li>
</ul>
Image: Shutterstock

Media

ACHR

ANET

ILMN

LRCX

PLTR

TSLX

Jim Cramer Says Illumina Is 'Challenged,' Recommends Selling This Industrial Stock

Across the recent three months, 4 analysts have shared their insights on Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Steris and provided 12-month price targets. The average target is $258.75, accompanied by a high estimate of $265.00 and a low estimate of $240.00. This current average has increased by 0.49% from the previous average price target of $257.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1738879437_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A comprehensive examination of how financial experts perceive Steris is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reni Benjamin</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$265.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Jacob Johnson</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$240.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$265.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>David Turkaly</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$265.00</td>
<td>$265.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Steris. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Steris compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Steris's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Steris's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/STE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Steris analyst ratings.</a>
<h2>About Steris</h2>
Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Additionally, Steris sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 19% from Applied Sterilization Technologies, or AST, and 11% from life sciences services after the divestment of its dental products business.
<h3>Steris: Delving into Financials</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Over the 3 months period, Steris showcased positive performance, achieving a revenue growth rate of 7.33% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Steris's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 11.29%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Steris's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 2.32%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Steris's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 1.47%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.36.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 4 Analyst Projections For Steris

Press Releases

STERIS to Host a Conference Call for Fiscal 2025 Second Quarter Financial Results on November 7, 2024

Dividends

STERIS Declares Dividend of $0.57 per share

Comments

Steris

뉴스

파트너 / 기고자

벤징가 글로벌